Translational medicine, which is a branch of medical research that connects basic research more directly to patient care, has received increasing attention in the medical profession. In the case of drug development, translational medicine typically refers to the translation of basic research into real therapies for real patients. More specifically, Pizzo has defined translational medicine as bench-to-bedside research, wherein a basic laboratory discovery becomes applicable to the diagnosis, treatment or prevention of a specific disease, and is brought forth by either a physician-scientist who works at the interface between the research laboratory and patient care, or by a team of basic and clinical science investigators. 1 Thus, translational medicine refers to the translation of basic research discoveries into clinical applications. In particular, translational medicine takes the discoveries of basic research to patients and measures endpoints in patients. Recently, scientists have become increasingly aware that translational research should be regarded as a two-way street, 2 i.e. bench-to-bedside and bedside-to-bench. Basic scientists provide clinicians with new tools for use with patients and for assessment of their impact, and clinical researchers make novel observations about the nature and progression of disease that often stimulate basic investigations. Mankoff et al pointed out that there are three major obstacles to effective translational medicine in practice, which are the challenge of translating basic scientific discoveries into clinical studies, the translation of clinical studies into medical practice and health care policy, and the misconception that basic science will produce efficiently novel therapies for human testing. identifying a functional relationship between some independent parameters observed in basic research discoveries and a dependent variable observed from clinical application; (2) based on the data observed in the study, conducting some model-fitting analysis to establish a predictive model between the independent parameters and the dependent response variable; and (3) validating the established predictive model and assessing whether the translational process is accurate and reliable with statistical assurance. For example, in drug development programs, the independent variables may include in vitro assay results, pharmacologic activities such as pharmacokinetics and pharmacodynamics, and dose toxicities, and the dependent variable could be a clinical outcome (e.g. a safety parameter). Statistical methods related to (1) and (2) are well documented in statistical literature. However, research effort is needed to develop appropriate criteria to assess the accuracy of a one-way and two-way translation process.
The purpose of this article is to introduce basic statistical concepts and propose statistical tests for one-way and two-way translation between basic research discoveries and clinical outcome, under a well-established and validated predictive model. In the next section on One-way Translation, the concept of one-way translation is introduced. Also included in this section are two proposed criteria and the corresponding statistical test for one-way translation. The Twoway Translation section proposes a procedure for evaluation of two-way translation. Statistical assessment of the lost in translation is briefly discussed in the section Lost in Translation. This is followed by some concluding remarks in the last section.
One-way Translation
Let x and y be the observed values from basic research discoveries and clinical application, respectively. In practice, it is important to ensure that the translational process is accurate and reliable, with some statistical assurance. One of the statistical criteria is to examine the closeness between the observed response y and the predicted response via a translational process. To study this, we will first study the association between x and y and build up a model, and then validate the model based on some criteria. For simplicity, we assume that x and y can be described by the following linear model: (1) where e follows a normal distribution with mean 0 and variance .
Suppose that n pairs of observations (x 1 , y 1 ), …, (x n , y n ) are observed in a translation process. 
1ˆ. 
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Measures of closeness
We may validate the translation model by considering how close are an observed y and its predicted value obtained based on the fitted regression model given by (2) . To assess the closeness, we propose the following two measures, which are based either on the absolute or the relative difference between y and :
Criterion I
Criterion II
In other words, we want a high probability that the difference or the relative difference between y and , given by p 1 and p 2 respectively, is less than a clinically or scientifically meaningful difference d. Then, for either i = 1 or 2, it is of interest to test the following hypotheses:
where p 0 is some prespecified constant. If the conclusion is to reject H 0 in favor of H a , this would imply that the established model is considered validated. The steps in carrying out the test of hypothesis corresponding to the two criteria are outlined in the following section, and the corresponding technical details in deriving the test results are given in the Appendixes.
Measure of closeness based on absolute difference
It is easy to show that where Φ is the cumulative density function of a standard normal distribution. Thus, the MLE of p 1 is given by Define where f(z) is the probability density function of a standard normal distribution. For a sufficiently large sample size n, using Slutsky's theorem, can be approximated by a standard normal distribution. 4 Details of the derivation can be found in Appendix I. Based on these results, for the testing of the hypotheses 
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. ( 1 ) ( 1 ) e e p c c Thus, the hypotheses given in (3) for one-way translation based on the probability of relative difference can be tested. In particular, H 0 is rejected if where z 1−α is the 100(1−a) th percentile of a standard normal distribution. Note that is an estimate of var and can be evaluated by simply replacing the parameters with their corresponding estimates of the parameters.
An example
For the two measures proposed in the above section, p 1 is based on the absolute difference between y and . Given α, p 0 and the selected observation For the purposes of illustration, suppose that the following data are observed in a translational study, where x is a given dose level and y is the associated toxicity measure:
When this set of data is fitted to model (1), the estimates of the model parameters are given by Thus, based on the fitted results, given x = x 0 , the proposed translation model is given by
In this study, choose α = 0.05 and p 0 = 0.8. In particular, two dose levels x 0 = 1.0 and 5.2 are considered. Based on the study, the corresponding toxicity measures y 0 are 1.2 and 9.0, respectively. However, based on the translation model, the predicted toxicity measures are 1.147 and 8.921, respectively. In the following, the validity of the translation model is assessed by the two proposed closeness measures p 1 and p 2 , respectively. Without loss of generality, choose α = 0.05 and p 0 = 0.8. 
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Two-way Translation
Validation of a two-way translational process
The translational process described in the section above is usually referred to as one-way translation in translational medicine. That is, the information observed at basic research discoveries is translated to the clinic. As indicated by Marincola, the translational process should be a two-way translation. 1, 2 In other words, we can exchange x and y in (1): (4) and come up with another predictive model . Along similar lines, using either one of the measures p i , the validation of a two-way translational process can be summarized by the following steps: (5) where . Note that the evaluation of p xi is much easier and can be computed in a similar way by interchanging the role of x and y for the results given in Measures of closeness in the previous section above.
An example (continued)
Using the data set given in An example in the previous section above, we set up the regression model x = g 0 + g 1 y + e, with y as the independent variable and x as the dependent variable. y y x x p P y x 
Lost in Translation
It can be noted that d y and d x can be viewed as the maximum bias (or possible lost in translation) from the one-way translation (e.g. from basic research discovery to the clinic) and from the other way of translation (e.g. from the clinic to basic research discovery), respectively. If d y and d x given in steps 2 and 4 of Validation of a two-way translational process are close to 0, with a relatively high probability, then we conclude that the information from the basic research discoveries (the clinic) is fully translated to the clinic (basic research discoveries). Thus, one may consider the following parameter to measure the degree of lost in translation: z = 1 -p xy p yx , where p xy is the measure of closeness from x to y, and p yx is the measure of closeness from y to x. When z ≈ 0, we consider that there is no lost in translation. Overall lost in translation could be significant, even when lost in translation from the one-way translation is negligible. For illustrative purposes, if there is a 10% lost in translation in one-way translation and 20% lost in translation the other way, there would be up to 28% lost in translation. In practice, an estimate of z can be obtained for a given set of data (x, y). In particular, As an illustration, consider the section An example (continued) above. Suppose that the measure of closeness based on relative difference is used, given (x 0 , y 0 ) = (1.0, 1.2) and (5.2, 9.0), the corresponding lost in translation for the two-way translation with d = 1 is tabulated here:
Concluding Remarks
A commonly asked question in translational medicine is whether results obtained based on an animal model can be predictive, through a translational process, of a human model. This question has to be addressed by testing for one-way and two-way translation, and considering the similarity between an animal and human model. In a more general context, Chow et al proposed the idea of a sensitivity index when changing from one population to another, and explored how the effect size under the human population is inflated (or reduced) by the sensitivity index. 6 In particular, this sensitivity index is a function of the shift in population mean and/or in population standard deviation from one population to the target population. Chow et al derived statistical inference of the sensitivity index for various patterns of the shifts in population mean and population variance. 7 In summary, translational medicine is a multidisciplinary entity that bridges basic scientific research with clinical development. As the expense in developing therapeutic pharmaceutical compounds continues to increase and the success rates for getting such compounds approved for marketing and to the patients needing these treatments continues to decrease, a focused effort has emerged in improving the communication and planning between basic and clinical science. Translational medicine contributes to the advancement of clinical care through collaboration between scientists and clinicians, which may lead to a substantial increase in the number of safe and effective compounds available to combat human diseases in a more efficient way. However, in the process, statistical methodology is an indispensable tool which provides a scientific and systematic way to extract useful information from the data collected in the process of decision making. As demonstrated in this study, the usefulness and validity of a translation process can be assessed by conducting relevant statistical inference based on some appropriate closeness measures. The results in this study help shed some insight into the use of different criteria, and certainly more research is needed in this direction. 
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